Click below to download the following important safety information.

News View All

$17,000 SolvayCARES^SM Scholarship Awarded to 2009 Thriving Student Achiever Read more...

Phase III Study Shows CREON^® Significantly Improves a Key Measure of Fat Absorption in Patients With Chronic Pancreatitis (CP) Read more...

Study Shows CREON^® Improves Absorption of Fat in Children With CF Read more...

Results of CREON^® Study Published in Journal of Cystic Fibrosis Read more...

SolvayCARES^SM

SolvayCARES^SMOverview

For more than 20 years, Solvay Pharmaceuticals, Inc., the marketer of FDA-approved CREON^®, has offered a variety of resources to support the CF community. Today, SolvayCARES^SM provides nutritional, educational, and financial support to patients, families, and healthcare professionals touched by CF. To enroll in SolvayCARES^SM and to review your options for ordering free nutritional drinks and supplements, click here.

Nutritional Support*

SolvayCARES^SM provides nutritional support with free multivitamins in softgel, chewable, and liquid formulations plus a variety of nutritional drink choices (some restrictions apply*).

Financial Support

Starting this year, SolvayCARES^SM is offering copay assistance up to $50 per month for the first 12 months for patients filling CREON^® prescriptions
(some restrictions apply*^†).

Educational Support

Over the past 17 years, SolvayCARES^SM has awarded scholarships totaling more than $2 million to bright, young students. For more information on the SolvayCARES^SM scholarship, click here.

Teaming Up to Fight CF

In keeping with the tradition of SolvayCARES^SM, Solvay Pharmaceuticals, Inc. has teamed with other organizations in the battle against CF. Since its inception in 1989, Solvay has been part of the Great Strides Walk to raise money for CF research. Solvay has also partnered with the Boomer Esiason Foundation (BEF) to help in the effort to find a cure for CF and other diseases. Through BEF, Solvay is proud to be the sponsor of the Sacks for CF scholarship program. For more information on Sacks for CF,
click here.

*For SolvayCARES^SM participants filling CREON^® prescriptions. Certain restrictions apply. Offer not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicare, Medicaid, any other federal or state program, or by private plans or other health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs. Offer void in Massachusetts for residents whose prescriptions are covered in whole or in part by third-party insurance, or where otherwise prohibited by law.

^†This offer is valid for up to $50 off your CREON^® prescription per month for the first 12 months.

INDICATION

CREON^® (pancrelipase) Delayed-Release Capsules is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Important Safety Information

Warnings and Precautions

Fibrosing colonopathy, a rare, serious adverse reaction has been described in association with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients.
Caution should be exercised when doses of CREON^® exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).

Care should be taken to ensure that CREON^® is not chewed or retained in the mouth to avoid irritation of oral mucosa.

Caution should be exercised when prescribing CREON^® to patients with gout, renal impairment, or hyperuricemia.

There is a theoretical risk of viral transmission with all pancreatic enzyme products including CREON^®.

Caution should be exercised when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Adverse Reactions

Treatment-emergent adverse events occurring in at least 2 patients (greater than or equal to 6%) receiving CREON^® or placebo are abdominal pain, abdominal pain upper, abnormal feces, cough, dizziness, flatulence, headache, and weight decreased. You are encouraged to report suspected adverse reactions. Please contact Solvay Pharmaceuticals, Inc. at 1-800-241-1643 or the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

SolvayCARESSMOverview

SolvayCARES^SMOverview